Recruiting Pulmonary Embolism Studies in Kalamazoo
Disengagement in CSC: Identifying Those at Risk and Addressing Their Needs
Maintaining treatment engagement is critical for first episode psychosis patients to experience gains possible with coordinated specialty care (CSC). This study is designed to identify CSC participant...
Artificial Intelligence to Measure Adherence to Oral Medication
The aims of this project is to use an artificial intelligence (AI) smartphone app to provide support for medication adherence by patients with first episode psychosis....
About Pulmonary Embolism Clinical Trials in Kalamazoo
Pulmonary embolism (PE) is a blockage of an artery in the lungs, usually caused by blood clots that travel from the deep veins of the legs. It can be life-threatening and requires immediate medical attention. Treatment includes anticoagulants and in severe cases, thrombolytic therapy.
There are currently 2 pulmonary embolism clinical trials recruiting participants in Kalamazoo, MICHIGAN. These studies are seeking a combined 500 participants. Research is being sponsored by Northwell Health. Clinical trial participation is free and participants receive study-related medical care at no cost.
Pulmonary Embolism Clinical Trials in Kalamazoo — FAQ
Are there pulmonary embolism clinical trials in Kalamazoo?
Yes, there are 2 pulmonary embolism clinical trials currently recruiting in Kalamazoo, MICHIGAN. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Kalamazoo?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Kalamazoo research site will contact you about next steps.
Are clinical trials in Kalamazoo free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Kalamazoo studies also compensate for your time and travel.
What pulmonary embolism treatments are being tested?
The 2 active trials in Kalamazoo are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary embolism.
Data updated March 2, 2026 from ClinicalTrials.gov